Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Topotecan price, strengths & recalls

Topotecan has no weekly pharmacy acquisition cost. 5 manufacturers make it. It has 2 recalls on record, none ongoing. Its official label last changed on February 3, 2021.

Generic
No weekly pricePharmacy acquisition costs aren't published for this drug - usually because it's given in clinics or hospitals.

Topotecan price by strength

What pharmacies pay for each strength and form this week, for the usual package. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
1 mg/mL injectionNot priced this week
1 mg/mL, 4 mL injectionNot priced this week
4 mg injectionNot priced this week

Supply status: shortages & recalls

No shortage reportedChecked Nov 16, 2026
No ongoing recalls2 recalls on record, latest Jul 14, 2021

Recalls

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for topotecan? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedFebruary 3, 2021
Version23 of 10
EffectiveFeb 1, 2021
Read the label

These highlights do not include all the information needed to use TOPOTECAN INJECTION safely and effectively. See full prescribing information for TOPOTECAN INJECTION. TOPOTECAN injection, for intravenous use Initial U.S. Approval: 1996

This drug has a boxed warning

WARNING: MYELOSUPPRESSION

Topotecan can cause severe myelosuppression. Administer first cycle only to patients with baseline neutrophil counts of greater than or equal to 1,500/mm3and platelet counts greater than or equal to 100,000/mm3. Monitor blood cell counts [see Warnings and Precautions (5.1)].

WARNING: MYELOSUPPRESSION

See full prescribing information for complete boxed warning.

Topotecan can cause severe myelosuppression. Administer first cycle only to patients with baseline neutrophil counts greater than or equal to 1,500/mm3 and platelet count greater than or equal to 100,000/mm3. Monitor blood cell counts. (2.2, 5.1)

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA200582 · Hospira Inc
First approved
February 2, 2011 (15 years ago)
Latest approved change
December 16, 2019
Approved label
PDF, Dec 17, 2019
Generic makers
4 approved generic applications on the market

Topotecan questions

Is topotecan in shortage?

No shortage is reported for topotecan right now. We check the national shortage list every day.

Has topotecan been recalled?

2 recalls on record, none ongoing. Recalls name specific lots - check yours.

When did the topotecan label last change?

The official label was last updated on February 3, 2021 (version 23). See what changed.

Talk about topotecan

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.